Biologic therapy is not associated with increased COVID-19 severity in patients with hidradenitis suppurativa: Initial findings from the Global Hidradenitis Suppurativa COVID-19 Registry

Haley B Naik,Raed Alhusayen,John Frew,Sandra Guilbault,Nancy K Hills,John R Ingram,Margaret V Kudlinski,Michelle A Lowes,Angelo Valerio Marzano,Maia Paul,Bente Villumsen,Christine A Yannuzzi

doi:10.1016/j.jaad.2021.09.016

Abstract

Biologic therapy is not associated with increased COVID-19 severity in patients with hidradenitis suppurativa: Initial findings from the Global Hidradenitis Suppurativa COVID-19 Registry

Highlights

Values in bold are values that are statistically significant (P value \.05)
To the Editor: Hidradenitis suppurativa (HS) patients may be at increased risk of severe COVID-19 and poor outcomes due to comorbidities and biologic treatment.[1]
COVID-19 cases in HS patients were reported in the Global Hidradenitis Suppurativa COVID-19 Registry from April 5, 2020, to February 2, 2021.1 Eligible cases had confirmed diagnosis of HS by a health care provider (HCP) or screening questions and COVID-19 diagnosis by an HCP

Summary

Introduction

Values in bold are values that are statistically significant (P value \.05). Cutoff value for statistical significance #.05. To the Editor: Hidradenitis suppurativa (HS) patients may be at increased risk of severe COVID-19 and poor outcomes due to comorbidities and biologic treatment.[1] COVID-19 cases in HS patients were reported in the Global Hidradenitis Suppurativa COVID-19 Registry (https://hscovid.ucsf.edu/) from April 5, 2020, to February 2, 2021.1 Eligible cases had confirmed diagnosis of HS by a health care provider (HCP) or screening questions and COVID-19 diagnosis by an HCP.

Results

Conclusion